Completed Enrollment

A Study of LY3461767 in Participants With Chronic Heart Failure With Reduced Ejection Fraction

J2L-MC-EZBB -

The main purpose of this study is to determine the tolerability and safety of LY3461767 with any side effects that might be associated with it. Study drug will be provided in a continuous subcutaneous infusion lasting 24 hours to 96 hours, depending on the cohort. Blood tests will be performed to check concentrations of LY3461767 in the bloodstream and how long it takes the body to get rid of it in participants with chronic heart failure with reduced ejection fraction (HFrEF).

Trial Summary

Age Range
18 - 80 years
Conditions the trial is for
Heart Failure
What the trial is testing?
LY3461767
Could I receive a Placebo?
Yes
Enrollment Goal
50
Trial Dates
Jun 1, 2021 - Jul 2024
How long will I be in the trial?
Your participation could last about 3 months and may include up to 5 visits to the study center.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must be males and in agreement to follow contraceptive requirements, or women of non-child-bearing potential

  • Participants must have a body mass index (BMI) of <= 45.0 kilograms per square meter (kg/m²)

  • Participants must have chronic stable heart failure (New York Heart Association (NYHA) classification II and III) on guideline directed heart failure therapy for at least 6 months prior to enrolment

  • Participants must have Left Ventricular Ejection Fraction (LVEF) < 40%

Participants Must Not:

  • Participants must not have heart attack, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke in the last 90 days prior to screening

  • Participants must not have acute decompensated heart failure requiring IV diuretics within 12 weeks prior to screening

  • Participants must not have cardiac amyloidosis, accumulation diseases (e.g., haemochromatosis, Fabry disease), muscular dystrophies, hypertrophic cardiomyopathy, pericardial constriction, or complex congenital heart disease

  • Participants must not have a history or presence of hepatic, pancreatic, or biliary tract disorders

  • Participants must not have a history of malignancy or active malignancy at screening

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.

Clinical Trial Resources